16 September 2026 editorial review · Item
Verapamil (oral): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: Pediatric verapamil RCT modest C-peptide preservation and exploratory off-drug loss checked; bradycardia/AV block monitoring remains relevant. No approved T1D disease-modifying indication.
- Registry NCT02372253: COMPLETED; updated 2020-02-05; enrollment 32 (ACTUAL); primary completion 2017-12 (ACTUAL); results posted.
- Registry NCT04233034: COMPLETED; updated 2024-11-27; enrollment 113 (ACTUAL); primary completion 2022-09-15 (ACTUAL); results posted.
- Registry NCT04545151: COMPLETED; updated 2026-05-20; enrollment 136 (ACTUAL); primary completion 2025-04-23 (ACTUAL); results not posted in retrieved record.
- Registry NCT07061574: RECRUITING; updated 2026-09-02; enrollment 120 (ESTIMATED); primary completion 2030-04-15 (ESTIMATED); results not posted in retrieved record.
- Primary publication/regulatory sources checked or consulted: s41467-022-28826-3; jama.2023.2064; bmjopen-2024-091597; s00125-024-06205-5; 000525824.